Itvisma, an intrathecal version of Zolgensma, can be used in children, teens and adults to stabilize or improve motor ...
The FDA has approved Itvisma (onasemnogene abeparvovec-brve) to treat children two years and older, teens, and adults living with spinal muscular atrophy (SMA). It is indicated for patients with a ...
Itvisma has the same active ingredient as Novartis' Zolgensma, but is approved for a broader population of older patients with an intrathecal formulation.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback